TELA Bio Approves Key Proposals at Annual Meeting

TELA Bio ( (TELA) ) just unveiled an update.

On May 28, 2025, TELA Bio, Inc. held its Annual Meeting of Stockholders where several key proposals were approved. The stockholders voted to amend the 2019 Equity Incentive Plan by increasing the authorized shares by 3,500,000 and removing the ‘evergreen’ provision. Additionally, the election of Class III directors, the ratification of KPMG LLP as the independent public accountant, and the approval of executive compensation were confirmed. The amendment to the company’s Certificate of Incorporation to limit officer liability was also approved, reflecting strategic governance adjustments.

The most recent analyst rating on (TELA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.

Spark’s Take on TELA Stock

According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.

TELA Bio demonstrates robust revenue growth and strategic positioning for future expansion. However, the stock’s financial health is undermined by ongoing losses, high leverage, and negative cash flows. Technical indicators reflect a bearish market sentiment, and the lack of profitability complicates valuation. Earnings call insights are positive but overshadowed by financial concerns, resulting in a moderate overall score.

To see Spark’s full report on TELA stock, click here.

More about TELA Bio

TELA Bio, Inc. operates in the medical technology industry, focusing on the development and commercialization of innovative soft tissue reconstruction solutions. The company primarily offers products designed for hernia repair and abdominal wall reconstruction, with a market focus on improving patient outcomes and reducing healthcare costs.

Average Trading Volume: 264,295

Technical Sentiment Signal: Sell

Current Market Cap: $54.98M

For detailed information about TELA stock, go to TipRanks’ Stock Analysis page.